Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG CLDE225XUS20

Title
Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 5 - LDE225 for patients with PTCH1 and SMO mutated tumors
Principal Investigator
Young Kwang Chae
Details
  • Status: CLOSED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG CLDE225XUS20
Purpose
Researchers want to know if LDE225 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a PTCH1 and/or SMO activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
Overview
LDE225 is a drug that is being developed for different tumor types and/or blood malignancies. LDE225 is an investigational drug that works by slowing down an important pathway (PTCH1 and/or SMO) inside the cell involved in the development of certain types of cancers. This pathway (PTCH1 and/or SMO) is thought to play a role in cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.
Eligibility
Some of the eligibility criteria include:
  • Participants must have a select solid tumor (except a type of brain cancer called medulloblastoma, basal cell skin carcinoma or pancreatic cancer) or a hematological malignancy (except chronic myelogenous leukemia, acute lymphoblastic leukemia or acute myelogenous leukemia).
  • Participants must need treatment for their cancer because it has relapsed (returned after prior treatment).
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
In this study, a complete dosing cycle is 28 days. In each cycle, participants will take LDE225 orally (by mouth) once a day.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Young Kwang Chae

last updated: 21-Dec-14 08:03 PM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.